Lim KB. Epidemiology of clinical benign prostatic hyperplasia. Asian J Urol. 2017;4(3):148–51.

Article  PubMed  PubMed Central  Google Scholar 

Gravas S, Cornu JN DM et al. EAU Guidelines: management of non-neurogenic male LUTS [Internet]. 2020. https://uroweb.org/guideline/treatment-of-non-neurogenic-male-luts/

Insausti I, Sáez de Ocáriz A, Galbete A, Capdevila F, Solchaga S, Giral P, et al. Randomized comparison of prostatic artery embolization versus transurethral resection of the prostate for treatment of benign prostatic hyperplasia. J Vasc Interv Radiol. 2020;31(6):882–90.

Article  PubMed  Google Scholar 

Abt D, Müllhaupt G, Hechelhammer L, Markart S, Güsewell S, Schmid H-P, et al. Prostatic artery embolisation versus transurethral resection of the prostate for benign prostatic hyperplasia: 2-year outcomes of a randomised, open-label single-centre trial. Eur Urol. 2021;80(1):34–42.

Article  PubMed  Google Scholar 

Gao Y, Huang Y, Zhang R, Yang Y, Zhang Q, Hou M, et al. Benign prostatic hyperplasia: prostatic arterial embolization versus transurethral resection of the prostate–a prospective, randomized, and controlled clinical trial. Radiology. 2014;270(3):920–8.

Article  PubMed  Google Scholar 

Carnevale FC, Iscaife A, Yoshinaga EM, Moreira AM, Antunes AA, Srougi M. Transurethral resection of the prostate (TURP) versus original and PErFecTED prostate artery embolization (PAE) due to benign prostatic hyperplasia (BPH): preliminary results of a single center, prospective urodynamic-controlled analysis. Cardiovasc Intervent Radiol. 2016;39(1):44–52.

Article  PubMed  Google Scholar 

Pisco JM, Bilhim T, Pinheiro LC, Fernandes L, Pereira J, Costa NV, et al. Medium- and long-term outcome of prostate artery embolization for patients with benign prostatic hyperplasia: results in 630 patients. J Vasc Interv Radiol. 2016;27(8):1115–22.

Article  PubMed  Google Scholar 

Patel NR, Elterman DS, Thulasidasan N, Altman R, Tai E, Zener R, et al. Initial Canadian experience of prostate artery embolization for symptomatic benign prostatic hyperplasia: midterm outcomes. Can Assoc Radiol J = J l’Assoc Can des Radiol. 2021;72(4):876–82.

Article  Google Scholar 

Ray AF, Powell J, Speakman MJ, Longford NT, DasGupta R, Bryant T, et al. Efficacy and safety of prostate artery embolization for benign prostatic hyperplasia: an observational study and propensity-matched comparison with transurethral resection of the prostate (the UK-ROPE study). BJU Int. 2018;122(2):270–82.

Article  PubMed  Google Scholar 

Uflacker A, Haskal ZJ, Bilhim T, Patrie J, Huber T, Pisco JM. Meta-analysis of prostatic artery embolization for benign prostatic hyperplasia. J Vasc Interv Radiol. 2016;27(11):1686-1697.e8.

Article  PubMed  Google Scholar 

National Institute for Health and Care Excellence. Guidance on Prostate artery embolization for benign prostatic hyperplasia 2018. [Internet]. https://www.nice.org.uk/guidance/ipg611/chapter/1-Recommendations

Foster HE, Barry MJ, Dahm P, Gandhi MC, Kaplan SA, Kohler TS, et al. Surgical management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline. J Urol. 2018;200(3):612–9.

Article  PubMed  Google Scholar 

Patel N, Yung N, Vigneswaran G, de Preux L, Maclean D, Harris M, et al. 1-year cost-utility analysis of prostate artery embolization (PAE) versus transurethral resection of the prostate (TURP) in benign prostatic hyperplasia (BPH). BMJ Surg Interv Heal Technol. 2021;3(1):e000071.

Article  Google Scholar 

Ontario Health (Quality). Prostatic artery embolization for benign prostatic hyperplasia: a health technology assessment. Ont Health Technol Assess Ser. 2021;21(6):1–139.

PubMed Central  Google Scholar 

Rink JS, Froelich MF, McWilliams JP, Gratzke C, Huber T, Gresser E, et al. Prostatic artery embolization for treatment of lower urinary tract symptoms: a Markov model-based cost-effectiveness analysis. J Am Coll Radiol. 2022;19(6):733–43.

Article  PubMed  Google Scholar 

Wu X, Zhou A, Heller M, Kohlbrenner R. Prostatic artery embolization versus transurethral resection of the prostate for benign prostatic hyperplasia: a cost-effectiveness analysis. J Vasc Interv Radiol. 2022;33(12):1605–15.

Article  PubMed  Google Scholar 

Capdevila F, Insausti I, Galbete A, Sanchez-Iriso E, Montesino M. Prostatic artery embolization versus transurethral resection of the prostate: a post hoc cost analysis of a randomized controlled clinical trial. Cardiovasc Intervent Radiol. 2021;44(11):1771–7.

Article  PubMed  PubMed Central  Google Scholar 

Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated health economic evaluation reporting standards (CHEERS) statement. Value Heal J Int Soc Pharmacoeconom Outcomes Res. 2013;16(2):e1-5.

Article  Google Scholar 

Napa lLecumberri S, Insausti Gorbea I, de Sáez Ocáriz García A, Solchaga Álvarez S, Cebrián Lostal JL, Monreal Beortegui R, et al. Prostatic artery embolization versus transurethral resection of the prostate in the treatment of benign prostatic hyperplasia: protocol for a non-inferiority clinical trial. Res Rep Urol. 2018;10:17–22.

Google Scholar 

Vallejo-Torres L, García-Lorenzo B, Serrano-Aguilar P. Estimating a cost-effectiveness threshold for the Spanish NHS. Health Econ. 2018;27(4):746–61.

Article  PubMed  Google Scholar 

Kok ET, McDonnell J, Stolk EA, Stoevelaar HJ, Busschbach JJV. The valuation of the international prostate symptom score (IPSS) for use in economic evaluations. Eur Urol. 2002;42(5):491–7.

Article  PubMed  Google Scholar 

Bermingham SL, Hodgkinson S, Wright S, Hayter E, Spinks J, Pellowe C. Intermittent self catheterisation with hydrophilic, gel reservoir, and non-coated catheters: a systematic review and cost effectiveness analysis. BMJ. 2013;346:e8639.

Article  PubMed  PubMed Central  Google Scholar 

Müllhaupt G, Hechelhammer L, Engeler DS, Güsewell S, Betschart P, Zumstein V, et al. In-hospital cost analysis of prostatic artery embolization compared with transurethral resection of the prostate: post hoc analysis of a randomized controlled trial. BJU Int. 2019;123(6):1055–60.

Article  PubMed  PubMed Central  Google Scholar 

Bagla S, Smirniotopoulos J, Orlando J, Piechowiak R. Cost analysis of prostate artery embolization (PAE) and transurethral resection of the prostate (TURP) in the treatment of benign prostatic hyperplasia. Cardiovasc Intervent Radiol. 2017;40(11):1694–7.

Article  PubMed  Google Scholar 

Bilhim T, Costa NV, Torres D, Pinheiro LC, Spaepen E. Long-term outcome of prostatic artery embolization for patients with benign prostatic hyperplasia: single-centre retrospective study in 1072 patients over a 10-year period. Cardiovasc Intervent Radiol. 2022;45(9):1324–36.

Article  PubMed  Google Scholar 

Gilfrich C, May M, Fahlenbrach C, Günster C, Jeschke E, Popken G, et al. Surgical reintervention rates after invasive treatment for lower urinary tract symptoms due to benign prostatic syndrome: a comparative study of more than 43,000 patients with long-term followup. J Urol. 2021;205(3):855–63.

Article  PubMed  Google Scholar 

Malde S, Umbach R, Wheeler JR, Lytvyn L, Cornu J-N, Gacci M, et al. A systematic review of patients’ values, preferences, and expectations for the diagnosis and treatment of male lower urinary tract symptoms. Eur Urol. 2021;79(6):796–809.

Article  PubMed  Google Scholar